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Hepasphere 50–100 lmAbstract Objective: This study examined the efﬁcacy of transarterial chemoembolization of unre-
sectable hepatocellular carcinoma using hepasphere 50–100 lm.
Methods: A total number of 52 patients with radiologically documented HCC [Child–Pugh score A
and B; 32 and 20 respectively] were embolized with hepasphere 50–100 lm. Forty-six patients were
HCV positive and 6 patients were HBV positive. Local response of the tumor was evaluated radi-
ologically after 1, 3, 6, 9 months and one year.
Results: TACE with hepasphere 50–100 lm was tolerated by all patients with no major complica-
tions. The total number of lesions in 52 patients was 67 lesions. Complete response was seen in 40
patients (76.9%), while residual lesions seen in 12 patients (23.1%). As regards complications, 48
patients (92.4%) developed post-embolization syndrome, 2 patients (3.8%) had isolated partial
IVC thrombosis while 2 patients (3.8%) showed combined partial IVC thrombosis and partial
thrombosis of posterior branch of right portal vein.
Conclusion: Hepasphere 50–100 lm is efﬁcient for the treatment of hypervascular HCC. Further
advances in drug-eluting beads including their size tailored to tumor anatomy may improve the
results. Large series of patients, follow up for longer periods and comparison with conventional
TACE and TACE with other DEB are needed.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Primary and secondary hepatic malignancies comprise a signif-
icant oncological problem, with tremendous mortality and
morbidity. Hepatocellular carcinoma (HCC) is the ﬁfth most
958 T. Amer et al.common cancer and the third leading cause of cancer related
mortality worldwide (1). Nearly 500,000 cases of HCC
representing more than 5% of all cancers are diagnosed every
year (2).
Hepatic resection is the initial treatment of choice for local-
ized hepatic malignancies in patients without macrovascular
invasion and with well-preserved hepatic function.
Unfortunately, only a limited number of patients are candi-
dates for hepatic resection. There are signiﬁcant recurrence
rates of HCC in patients after surgical resection of 50% at
3 years and 70% at 5 years. Although recent advances in sur-
gical techniques and preoperative care have reduced morbidity
and mortality related to liver resection, the postoperative
complication rate remains as high as 42% in patients with
cirrhosis (3).
For the patients with unresectable tumors, chemotherapy
would be necessary to treat primary HCC or secondary metas-
tases. Over the years, clinical studies have been carried out to
broaden the treatment options. These include systemic
chemotherapy, adjuvant therapy, and intra-arterial
approaches (4). Palliative therapies via transarterial chemoem-
bolization (TACE) are used for hepatic malignancies not
amenable for surgical therapy (5–7).
The simplest form of transarterial chemoembolization
(TACE) involves a two-step process, namely (1) intra-arterial
administration of chemotherapeutic agents into the tumor-
feeding artery via an intraarterially inserted catheter, and (2)
selective embolization of the tumor-feeding artery (8,9).
More recently, advances have been made in the materials
design, such that the embolic agent itself could be a drug car-
rier, which appears to be a more convenient and efﬁcient pro-
cedure. Speciﬁcally these drug loaded carriers are directly
injected intra-arterially for the treatment of liver cancer in
one operation. Often this kind of drug carrier is referred to
the drug-eluting beads (DEB), in the literature typical exam-
ples include, hepasphere and irinotecan-eluting beads (9).
Hepasphere (Biosphere Medical Rockland, MA, USA) is
biocompatible hydrophilic (absorbent), nonresorbable and
expandable microsphere. Hepasphere conformable and swell
upon exposure to aqueous solution. It is made of sodium acry-
late and vinyl alcohol copolymer. The dry microspheres are
supplied in a range of sizes namely 30–60 lm, 50–100 lm,
100–150 lm and 150–200 lm (10).
The aim of this study is to examine the safety and efﬁcacy
of transarterial chemoembolization (TACE) of unresectable
HCC using hepasphere 50–100 lm drug eluting beads.2. Materials and methods
This study was a prospective study, started at July 2012 and
completed at May 2014. All the patients gave informed con-
sent, and the study was approved by the institutional Ethics
Committee. It included 52 patients (44 male and 8 female
patients) with radiologically documented HCC according to
the American Association for study of liver disease
(AASLD). Their ages ranged from 48 to 74 years (mean age
was 58.15 years). Patients enrolled were Child–Pugh A in 32
patients (61.5%) and Child–Pugh B in 20 patients (38.5%).
All the lesions were not suitable for heat ablation. Inclusion
criteria were single lesion >5 cm and located at critical site
either adjacent to blood vessel, GIT or subcapsular or multiplelesions which were more than 3 cm each. Liver functions pre-
requisites for enrollment included serum bilirubin below
2 mg/dl, albumin more than 3 g/dl and prothrombin concen-
tration more than 60%. Exclusion criteria included previous
history of hepatic resection for hepatic tumor, patients with
previous history of local tumor ablation, either with radiofre-
quency ablation (RFA) or microwave ablation (MWA),
patients with history of treatment with doxorubicin before,
patients with arteriovenous shunt by CT scan, extrahepatic
disease and patients with portal vein thrombosis.
2.1. Imaging
All images were performed using multidetector CT scan.
Baseline triphasic CT scan and another CT scan 4 weeks after
the ﬁrst session of TACE were obtained, then triphasic CT
scan 3 months, 6 months, 9 months and one year after the pro-
cedure. All the CT examinations were performed using
Brilliance-16 scanner (Philips Medical system, Cleveland,
USA), at three phases: arterial, portal and delayed venous
phases.
2.2. Response assessment
Response assessment was evaluated according to (mRECIST)
modiﬁed Response Evaluation Criteria In Solid Tumor. If
there was still residual enhanced lesion in arterial phase, more
than one centimeter in diameter with typical washout in the
portal and venous phases, it was considered residual tumor
or partial response. Totally hypovascular non-enhanced
masses in the arterial phase were considered totally ablated
lesions. Response assessment was completed with alpha feto
protein (AFP) assessment one month after TACE with hepas-
phere compared to its baseline level, before TACE.
2.3. Technique of TACE
All angiographic techniques and TACE (67 sessions) for 52
patients were performed in well prepared angiographic and
interventional room using MD Eleva machine (Philips
Medical system, Cleveland, USA). All procedures were per-
formed via the right transfemoral route. After shaving of the
groin and sterilizing the skin with antiseptics, local anesthesia
using 10 ml of Xylocaine (Lidocaine hydrochloride 2%) was
performed. Then puncture of the right common femoral artery
using modiﬁed Seldinger technique and catheterization of the
abdominal aorta over, 0.35 Terumo guide wire, then catheter-
ization of the hepatic artery whether arising from the celiac
trunk or superior mesenteric artery using 5 F cobra head
catheter were done for vascular mapping. Then catheterization
of the tumor feeding artery whether selective or superselective
using microcatheter 2.4 Terumo was done. Then after being
sure of selective catheterization of the tumor feeding artery,
pre-embolization angiogram was obtained, followed by slow
injection of doxorubicin-hepasphere mixture under ﬂuo-
roscopy. During injection of the embolic agent multiple angio-
graphic controls were obtained to avoid reﬂux of the embolic
agent to other areas of the liver. If stasis of contrast was seen
inside the tumor a waiting time of 3–5 min was done followed
by injection of hepasphere in order to be sure from good dis-
tribution in the feeding artery as well as tumor bed. Then more
Table 1 Demographics, main liver functions and size of
lesions in 52 patients.









+HBV 6 (11.5%) 52 (100%)
Mean ± SD (Minimum–
maximum)
Age 58.15 ± 7.24 year (48–74)
Albumin 3.2 ± 0.45 g/dl (2.6–4.2)
Bilirubin 1.3 ± 0.36 mg/dl (0.9–2.1)
Prothrombin concentration 70.6 ± 8.7% (60–88)
Size of lesions 4.6 ± 1.5 cm (2.5–8.5 cm)
Alphafetoprotein before
procedure
1154 ± 1143.3 ng/
dl
(28–3550)
Table 2 Number of lesions in each liver lobe and both
together in 52 patients.
Site of lesions Number of
lesions
N (%) Total no. of
cases
Single 41 (78.8%) 52 (100%)
Two 7 (13.5%)
Three 4 (7.7%)
Right lobe lesions No 2 (3.8%) 52 (100%)
Single 39 (75%)
Two 11 (21.2%)
Left lobe lesions No 46 (88.5%) 52 (100%)
One 6 (11.5%)
Both lobes lesions No 48 (92.3%) 52 (100%)
Yes 4 (7.7%)
N= number of patients. %= percent.
Table 3 Number of lesions previously treated and not treated
by TACE with lipidol.
Number of
patients
(%) Total number of
patients
No previous TACE with
lipidol
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injection. Then the catheter from microspheres was washed
by saline followed by slight backward withdrawal of the cathe-
ter and post-embolization angiogram.
2.4. Preparation of hepasphere
Every vial of hepasphere 50–100 lm was loaded with two vials
of doxorubicin powder 50 mg, per vial. Every vial of doxoru-
bicin was prepared by the addition of 20 ml of normal saline,
then 10 ml of saline–doxorubicin mixture was added to the vial
of hepasphere and agitated frequently for 10 min (steps sug-
gested by the manufacturer). Then the whole solutions of dox-
orubicin and hepasphere were added together in single 50 ml
syringe and agitated periodically for one hour for complete
ionic bonding of the doxorubicin. After the loading period
all supernatant ﬂuid was extracted and an equal quantity of
nonionic contrast medium was added (11).
2.5. Patient medication
Medications just before and during chemoembolization with
hepasphere included intravenous antibiotics, cefotax (cefo-
taxime) 750 mg, IV metronidazole/ﬂagyle 500 mg, and IV
analgesics as well as continuous dripping of IV ﬂuids.
After the procedure patient was discharged on the same
night from the hospital and was advised to take plenty of oral
ﬂuids, IV ﬂuids 1000 ml daily for two days, antibiotics as cefo-
tax 500 mg/8 h for 5 days and paracetamol 500 mg oral, only if
there is pain or fevers. Patients were advised to visit the hospi-
tal at any time if there is swelling or bleeding at the site of
puncture or if there is severe abdominal pain.
3. Results
This study included a total number of 52 patients. Their ages
ranged from 48 to 74 years (mean age was 58.15 years).
Thirty-two patients were Child–Pugh class A (61.5%), and
20 patients were Child–Pugh class B (38.5%). The size of
lesions ranged from 2.5 cm, in diameter up to 8.5 cm in diam-
eter with a mean size of 4.95 cm. Forty-six patients (88.5%)
had liver cirrhosis due to chronic HCV, while 6 patients were
HBV positive (11.5%). Patient demographics, main liver func-
tions, size of the lesions, gender and virology were listed in
Table 1.
The total number of lesions in 52 patients was 67 lesions.
Forty-one patients (78.8%) had isolated single lesion (41
lesion), 7 patients (13.5%) had two lesions (14 lesions), and 4
patients (7.7%) had 3 lesions (12 lesion). Right lobe lesions
were seen in 46 patients (88.5%), left lobe lesions were seen
in 2 patients (3.8%) and lesions in both lobes were seen in 4
patients (7.7%). The total number of lesions and frequency
of lesions in each lobe were listed in Table 2. Seven patients
(13.5%) were previously treated with lipidol-loaded doxoru-
bicin and had signiﬁcant residual tumor, while 45 patients
(86.5%) were treated from the start by hepasphere micro-
sphere (Table 3). Total treatment of the lesions with no signif-
icant residual tumor was achieved in 40 patients (76.9%), while
in 12 patients there was residual tumor that needs a second ses-
sion (Table 4), so the total number of sessions in 52 patients
was 67 sessions. Total response was noted in younger patient(56 ± 5 years) while partial response was patient in older
patient (64 ± 8 years) (P value < 0.001) (Table 5). No signif-
icant changes were detected as regards serum albumin, serum
bilirubin, prothrombin concentration, alphafetoprotein either
in complete or partial response after procedure, also the size
of lesion did not affect tumor response (P value was insigniﬁ-
cant) (Table 5). Good response and adequate tumor treatment
were seen in patients with single lesions, younger patients and
patients with relatively good liver functions, particularly
patients with serum albumin more than 3.2 g/dl. The level of
Table 6 Relation between the tumor treatment, number of






Number of lesions Single 37 (92.5%) 4 (33.3%) <0.001
Two 3 (7.5%) 4 (33.3%)
Three 0 (0%) 4 (33.3%)
Previous TACE with
lipidol
Yes 1 (2.5%) 6 (50%) <0.001
No 39 (97.5%) 6 (50%)
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Fig. 1 Shows efﬁcacy of the treatment of unresected multi-focal
hepatocellular carcinoma by 50–100 lm hepasphere versus the
number of lesions. Y-axis represents the number of treated
patients. X-axis represents the number of lesions. P value was
signiﬁcant <0.001.
Table 4 Number of patients with totally treated HCC and





Total ablation 40 76.9 52 (100%)
Residual ablation 12 23.1
960 T. Amer et al.serum bilirubin was of paramount. Poor response and high
rates of residual tumor were seen in patients with more than
one lesion, particularly patients with three lesions, this was
listed in Table 6 (see Fig. 1).
3.1. AFP levels and liver enzymes
There was a signiﬁcant decrease in the level of AFP after
embolization in this study. It was elevated in all patients.
Mean value of AFP before embolization was
(1154 ± 1143 ng/ml) and after embolization mean value
reaches about (32 ± 69.75 ng/ml). There was a signiﬁcant
decrease in the level of AFP after embolization denoting good
response (P< 0.001) Fig. 2 and Tables 1 and 5 (see Figs. 3–7).
3.2. Complications
There were no major complications or procedure related mor-
tality in this series. There was 0% mortality, one month, three
months, 6 months and 9 months. Only one mortality was seen
after 10 months as she developed liver dysfunction and ascites.
The most common complication in this study was postem-
bolization syndrome which was seen in 48 patients (92.3%)
and it was treated conservatively. Isolated partial IVC throm-
bosis was seen in 2 patients (3.8%). Associated partial IVC
thrombosis and partial thrombosis of the posterior division
of portal vein were seen also in 2 patients (3.8%). It was due
to the vicinity of the tumor to the IVC (Table 7). There was
a mild insigniﬁcant increase in liver enzymes in 50 patients
which was asymptomatic, while in two patients there was sig-
niﬁcant increase in liver enzymes (two and three folds increase
respectively), one of them was treated conservatively and
improved, while the second developed liver dysfunction,
marked ascites, and died after 10 months.
3.3. Statistical analysis
Statistical analysis was carried out via Statistical package for
social Science (SPSS) version 17 program on windows XP.Table 5 Group statistics in 52 patients with HCC.
Total treatment
Age 56.25 ± 5.77 year
Albumin 3.22 ± 0.467 g/dl
Bilirubin 1.3 ± 0.340 mg/d
Prothrombin concentration 70.75 ± 8.98%
Size of lesion 5.02 ± 1.48 cm
Alphafetoprotein before ablation 1130 ± 1169 ng/dl
Alphafetoprotein after ablation 22 ± 20.49 ng/dlQualitative data were represented in the form of number and
frequency, while quantitative data were represented in the
form of mean ± standard deviation (mean ± SD).
Kolmogorov–Smirnov test was used to test normality of quan-
titative data. v2, McNemar, Mann–Whitney U and Student’s
tests were used to compare variables. Results were considered
statistically signiﬁcant if p value is less than or equal 0.05.Residual tumor P value
64.5 ± 8.25 year <0.001
3.1 ± 0.571 mg/dl 0.717
l 1.3 ± 0.419 mg/dl 0.989
70.16 ± 8.37% 0.842
4.71 ± 1.59 cm 0.545
1043 ± 761 ng/dl 0.81
65 ± 139 ng/dl 0.72
AFP-Pre-embolization AFP.Post-embolization
Fig. 2 Box and whisker shows alphafetoprotein pre- and
postembolization with signiﬁcant P value <0.001.
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Conventional transcatheter arterial chemoembolization
(TACE) and chemoembolization with drug-eluting beads
(DEB-TACE) are increasingly being performedFig. 3 Right lobe HCC (segment 7) totally treated with no residual
fairly rounded mass with marked heterogenous enhancement. (B, C) Po
embolization selective right hepatic angiography shows the vascular tu
complete disappearance of the tumor vascularity with contrast staining
shows central hyperdensity mostly intra-tumoral blood. (G–I) Follow u
respectively) shows complete tumor treatment with no residual viable p
no residual tumor tissue.interchangeably in many institutions throughout the world.
As both therapies continue to being tested in many phase II
and III studies and in combination with other therapies, espe-
cially targeted agents, for the treatment of primary and meta-
static cancer liver, it is imperative to review their current status
and evaluate their impact on patient survival (12).
During the last few years drug-eluting beads have been used
in the treatment of unresectable hepatocellular carcinoma.
They proved to have good results (13–15,11). They proved to
have less toxicity compared with lipidol-based conventional
TACE (c-TACE) (16).
A number of studies with drug-eluting embolic materials
have concluded that smaller calibers of microspheres are
attractive because they achieve more distal embolization
(17,18). The new drug-eluting bead hepasphere microsphere
is a nontoxic and nonbiodegradable. The particle size is pre-
cisely calibrated in the dry state. The dry microspheres absorb
ﬂuid and swells within several minutes when exposed to
aqueous-based media. The swollen particle is reported to be
soft, and easily delivered through the majority of the currently
available microcatheters. The dry microspheres are supplied in
a range of sizes namely 50–100, 100–150 and 150–200 lm (9).
Hepasphere has been evaluated in an initial clinical study
which comprised 50 patients in four centers (19). The micro-
spheres were loaded either with doxorubicin (mean dosetumor. (A) Triphasic CT scan arterial phase shows a well deﬁned
rtal and delayed phases respectively show tumor washout. (D) Pre-
mor with tumor blush. (E) Post-embolization angiography shows
of the mass. (F) Follow up noncontrast CT liver after one month
p triphasic CT after one month (arterial, portal and delayed phases
art. (J) Follow up triphasic CT arterial phase after one year shows
Fig. 4 Left lobe HCC (segment 2) totally treated. (A) Triphasic CT scan arterial phase shows intensely enhanced left lobe mass. (B, C)
Triphasic CT (portal an delayed phases respectively) shows complete washout of the tumor. (D) Super-selective left hepatic angiography
(pre-embolization) shows well deﬁned rounded left lobe markedly vascular mass. (E) Post-embolization angiography shows disappearance
of the tumor vascularity. (F–H) Follow up triphasic CT scan (arterial, portal and delayed phases respectively) shows complete treatment
of the tumor.
962 T. Amer et al.43.7, 18.7 mg) or with epirubicin (mean dose 41.7, 14.6 mg). It
has been shown that TACE using hepaspheres is feasible, is
well tolerated, has low complication rate and is associated with
good tumor response (9).
This study was constructed mainly to study the efﬁcacy and
safety of TACE using the new microsphere hepasphere 50–
100 lm in patients with unresectable HCC. The results of this
study showed that hepasphere 50–100 lm is an effective
embolic agent, achieving major tumor necrosis and high rates
of response, where total ablation of the tumor with no residual
lesions was seen in 40 patients (76.9%) and residual tumors
were seen in 12 patients (23.1%). Hepasphere 30–60 lm were
used in 45 patients with HCC to study the efﬁcacy and safety
of these beads (11). Nearly they have the same results, where
they reported high rate of objective response about (68.9%).
They concluded that hepasphere microsphere 30–60 lm is an
effective and safe. Larger hepasphere achieved lower local
response rates with 32% objective response rates for lesions
5 cm (19). Larger hepasphere microsphere achieved a response
rate of 43.7% (20). Also it was obvious from this study that,
good response and total ablation of the tumor were seen in
patients with single lesion (41 patients), younger patients and
patients with relatively good liver functions, particularlypatients with serum albumin above 3.2 g/dl. In group statistics
total ablation was seen in younger patients (46.2 years), while
residual tumor was seen in older patients (64.0 years). Also
total ablation was seen in patients with relatively higher serum
albumin (3.21 g/dl) and residual lesions were seen in patients
with relatively low serum albumin (3.15 g/dl). The level of
serum bilirubin has no signiﬁcance in our study as in patients
with good response the mean serum bilirubin was 1.285 and in
patients with residual tumor the mean serum bilirubin was
1.283. Also in patients with hepatitis B infection, the response
was better as compared to the response in patients with
chronic HCV infection.
Grosso et al. stated that repeated TACE procedures have
been carried out without difﬁculties for the cases where com-
plete tumor response is not achieved, and they used large hep-
asphere (19). We have similar results in this study as residual
tumor after one session was seen in 12 patients where the pro-
cedure of TACE using hepasphere 50–100 lm was repeated
safely in the 12 patients. Smaller size of hepasphere as 30–
60 lm are new drug embolic agents that achieve homogenous,
effective and distal embolization. This is proved by study done
in pigs by Dinca et al. (21). The effective factor in good local
response of hepasphere 30–60 lm is its higher ﬂexibility in
Fig. 5 Right lobe HCC (segment 7) with residual tumor after ﬁrst session of hepasphere. (A) Triphasic CT arterial phase shows well
deﬁned rounded subcapsular mass with intense enhancement and small central necrosis. (B, C) Portal and delayed phases show tumor
washout. (D) Selective right hepatic angiography shows large right lobe markedly vascular mass with tumor blush. (E) Follow up triphasic
CT scan after one month arterial phase shows small residual viable part at the superomedial aspect of the tumor with marked
enhancement. (F) Follow up triphasic CT scan after one year, arterial phase, shows total treatment of residual tumor
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penetration of the smaller vessels inside the tumor bed (22–24).
Alpha feto protein level was used as an indicator for tumor
response and it was signiﬁcantly decreased. Its mean value
before embolization was 1154 ± 1143 ng/ml, while after
embolization, its mean value was signiﬁcantly lowered reach-
ing about 32 ± 69 ng/ml. According to Wilcoxon signed
Ranks test, there was a signiﬁcant decrease with P value
<0.001. In the study of Malagari et al., the mean values of
AFP levels before embolization (baseline) were
745.6 ± 27 ng/ml. Mean values after embolization were
219 ± 37 ng/ml. There was a statistically signiﬁcant decrease
in the levels of AFP after embolization indicating good
response of tumor to embolization (P< 0.001) (11).
The number and rates of complications in this study were
relatively small. There was no procedure related mortality, also
no mortality at 1 month, 3, 6 and 9 months. The only mortality
in this study was after 10 months, as the patient had chronic
HCV and liver cirrhosis on top (Child–Pugh class B), she
had right lobe HCC, 5.2 cm, in diameter. After single session
of TACE with hepasphere 50–100 lm she developed ascites
and liver dysfunction, shortly after the procedure, she was
treated conservatively, but after 10 months she developed liver
cell failure and died. In the study of Grosso et al., they used
hepasphere 50–100 lm, and they had relatively high rates of
complications, where they had 3% periprocedural mortality
(19). In the series of Malagari et al., they used hepasphere
microsphere 30–60 lm, in the treatment of 45 patients with
unresectable HCC, there was no procedure related mortalityand also there was no 30 day mortality. In this series there
was no liver abscess formation, no cholecystitis or hepatic
artery damage (11).
Postembolization syndrome was seen in 48 patients (92.4%)
and was treated conservatively. Partial thrombosis of the IVC
was seen in 4 patients (7.6%), this may be due to close contact
of the tumor with the IVC (Table 7). One of these patients
experienced severe abdominal pain during the procedure, trea-
ted by strong analgesics. Our explanation for this is either due
to extension of the tumor to the adjacent IVC or this extension
to the IVC was present before the embolization and it passed
unnoticed due to relatively poor quality of pre-embolization
CT scan, partial IVC thrombosis as a complication of this
technique was not reported before in the literature. Also par-
tial thrombosis of the posterior branch portal vein was seen
in 2 patients (3.8%) due to the vicinity of tumor to portal vein
branch.
The limitations of this study are low number of patients
(52) and it does not offer comparison remotely with con-
ventional TACE (C-TACE), receiving doxorubicin loaded
lipidol or comparison with TACE using other drug – elut-
ing beads.
In summary, hepasphere 50–100 lm is a highly effective
and safe embolic agent for HCC. Tumor necrosis is evident
shortly after TACE. However, further beads (DEB), including
their size, tailored to tumor anatomy may improve the results,
also large series of patients, follow up for longer periods and
comparison with C-TACE and TACE with other DEB are
needed.
Fig. 6 A case of right lobe multi-focal hepatoma with previous history of TACE with lipidol and still no response. (A) Triphasic CT scan
arterial phase shows two right lobe exophytic masses with intense enhancement and hyperdense traces of lipidol. (B, C) Portal and delayed
phases show complete washout of both masses. (D) Superselective right hepatic angiogram shows the larger mass with marked vascularity
and tumor blush. (E) Post-embolization angiogram shows complete disappearance of tumor vascularity. (F–H) Follow up triphasic study
after one month (arterial, portal and delayed phases respectively) shows complete treatment of larger tumor, while the smaller one is still
active showing tumor enhancement and washout. (I) Follow up triphasic CT arterial phase after one year shows complete ablation of
larger tumor and still active smaller one.
Fig. 7 A case of right lobe HCC with IVC thrombus after TACE with hepasphere. (A) Follow up triphasic CT after one month portal
phase shows complete tumor treatment and small partially occluding IVC thrombus. (B) Coronal reformatted image shows the treated
tumor and adjacent IVC thrombus.
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Table 7 Complications in 52 patients with HCC treated by
hepasphere 50–100 lm.
Number of patients Percent
Postembolization syndrome 48 92.3
IVC thrombus 2 3.8
PV thrombus + IVC thrombus 2 3.8
Total number of cases 52 100
IVC = inferior vena cava. PV = portal vein.
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None.
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